Pediatrix Medical Group, Inc. Q4 2025 Earnings Call Summary

Strong 2025 performance was driven by a combination of high patient acuity, favorable payer mix, and robust financial controls across the portfolio. Same-unit pricing growth of just under 7% resulted from improved revenue cycle management (RCM) cash collections and increased contract administrative fees. Volume declines of approximately 3% in the fourth quarter were attributed to difficult year-over-year comparisons rather than a fundamental shift in demand. Management implemented two new physician ...